Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Trimel Pharmaceutica (TRLPF)

Trimel Pharmaceutica (TRLPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Trimel Pharmaceutica 2486 Dunwin Drive Mississauga A6 L5L 1J9 CAN

www.aceruspharma.com P: 416-679-0771

Description:

Acerus Pharmaceuticals Corporation is a pharmaceutical company. The company is focused on the development, manufacture, marketing and distribution of branded products which improve the patient experience. The company's product include ESTRACE(R) which provides symptomatic relief of menopausal symptoms and NATESTO(TM) a bioadhesive intranasal gel formulation of testosterone. It also develops Tefina, an intranasal, low-dose gel formulation of testosterone for women experiencing female orgasmic disorder. Acerus Pharmaceuticals Corp, formerly known as Trimel Pharmaceuticals Corp, is headquartered in Mississauga, Canada.

Key Statistics

Overview:

Market Capitalization, $K 29,870
Shares Outstanding, K 258,615
Annual Sales, $ 7,380 K
Annual Net Income, $ -18,790 K
Last Quarter Sales, $ 2,070 K
Last Quarter Net Income, $ -5,050 K
60-Month Beta 2.60
% of Institutional Shareholders 0.02%
Float, K 258,615
% Float 100.00%

Growth:

1-Year Return -58.71%
3-Year Return 46.20%
5-Year Return -68.60%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 68.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 05/13/19
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Qtr -100.00%
EPS Growth vs. Prev Year -100.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

TRLPF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -346.72%
Return-on-Assets % -94.54%
Profit Margin % -254.61%
Debt/Equity -116.72
Price/Sales 4.21
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -9.60
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar